Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 19/20 | 0.74 |
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14361813 | 0.86 | PDE2A (0.82) | PDE2APDE10APDE4DPDE11AESR2 | |
| SCHEMBL12502536 | 0.85 | PDE2A (1.00) | PDE2APDE10APDE4DPDE11AESR2 | |
| SCHEMBL14765006 | 0.85 | PDE2A (0.81) | PDE2APDE10APDE4DPDE11AESR2 | |
| SCHEMBL14362126 | 0.83 | PDE2A (0.78) | PDE2APDE10APDE4DPDE11AESR2 | |
| SCHEMBL12503036 | 0.83 | PDE2A (1.00) | PDE2APDE10APDE4DPDE11A | |
| SCHEMBL12502680 | 0.83 | PDE2A (1.00) | PDE2APDE10APDE4DPDE11AESR2 | |
| SCHEMBL15555735 | 0.83 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12502893 | 0.82 | PDE2A (1.00) | PDE2APDE10APDE4DPDE11A | |
| SCHEMBL14361873 | 0.81 | PDE2A (0.83) | PDE2APDE10APDE4DPDE11A | |
| SCHEMBL14362064 | 0.81 | PDE2A (0.74) | PDE2APDE10APDE4DPDE11AESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723744-B1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-23 | — | — | EP | claimed |
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | claimed |
| EP-2723744-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2014-04-30 | — | — | EP | claimed |
| WO-2013000924-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-03 | — | — | WO | claimed |
| US-10604523-B2 | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-31 | — | — | US | disclosed |
| EP-2723744-B1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-23 | — | — | EP | disclosed |
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| EP-2723744-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013000924-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | PDE2A, PDE12, PDE5A | PDE2A 1/4885PDE10A 10/4885PDE4D 12/4885 |
| US-10604523-B2 | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives | PDE2A, PDE12, PDE5A | PDE2A 1/4885PDE10A 10/4885PDE4D 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.